W Stohl1, S Metyas, S-M Tan, G S Cheema, B Oamar, V Roschke, Y Wu, K P Baker, D M Hilbert. 1. Division of Rheumatology, Department of Medicine, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. stohl@usc.edu
Abstract
OBJECTIVE: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. METHODS: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. RESULTS: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. CONCLUSION: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.
OBJECTIVE: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity. METHODS: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation. RESULTS: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate. CONCLUSION: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.
Authors: Benjamin L Hsu; Susan M Harless; R Coleman Lindsley; David M Hilbert; Michael P Cancro Journal: J Immunol Date: 2002-06-15 Impact factor: 5.422
Authors: Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti Journal: Nat Immunol Date: 2002-08-05 Impact factor: 25.606
Authors: B Pradet-Balade; J P Medema; M López-Fraga; J C Lozano; G M Kolfschoten; A Picard; C Martínez-A; J A Garcia-Sanz; M Hahne Journal: EMBO J Date: 2002-11-01 Impact factor: 11.598
Authors: Soon-Min Tan; Dong Xu; Viktor Roschke; James W Perry; Daniel G Arkfeld; Glenn R Ehresmann; Thi-Sau Migone; David M Hilbert; William Stohl Journal: Arthritis Rheum Date: 2003-04
Authors: Nobuhiko Kayagaki; Minhong Yan; Dhaya Seshasayee; Hua Wang; Wyne Lee; Dorothy M French; Iqbal S Grewal; Andrea G Cochran; Nathaniel C Gordon; JianPing Yin; Melissa A Starovasnik; Vishva M Dixit Journal: Immunity Date: 2002-10 Impact factor: 31.745
Authors: Danielle T Avery; Susan L Kalled; Julia I Ellyard; Christine Ambrose; Sarah A Bixler; Marilyn Thien; Robert Brink; Fabienne Mackay; Philip D Hodgkin; Stuart G Tangye Journal: J Clin Invest Date: 2003-07 Impact factor: 14.808
Authors: Jens V Stein; Marta López-Fraga; Fernando A Elustondo; Carla E Carvalho-Pinto; Dolores Rodríguez; Ruth Gómez-Caro; Joan De Jong; Carlos Martínez-A; Jan Paul Medema; Michael Hahne Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808
Authors: Chaim O Jacob; Shunhua Guo; Noam Jacob; Rahul D Pawar; Chaim Putterman; William J Quinn; Michael P Cancro; Thi-Sau Migone; William Stohl Journal: Arthritis Rheum Date: 2012-05
Authors: Stacey R Dillon; Brandon Harder; Kenneth B Lewis; Margaret D Moore; Hong Liu; Thomas R Bukowski; Nels B Hamacher; Megan M Lantry; Mark Maurer; Cecile M Krejsa; Jeff L Ellsworth; Susan Pederson; Keith B Elkon; Mark H Wener; Maria Dall'Era; Jane A Gross Journal: Arthritis Res Ther Date: 2010-03-19 Impact factor: 5.156